CA-SENSEFORTH.AI
Conversational AI leader Senseforth.ai today announced a $14 million investment from Fractal (fractal.ai ), a global provider of artificial intelligence and analytics solutions to Fortune 500® companies. This investment will help Senseforth.ai scale and expand its footprint across Fractal’s clients globally. This investment also strengthens Fractal's conversational AI offerings as it advances on its mission to power every human decision in the enterprise.
Senseforth.ai’s patented and award winning zero-code platform A.ware automates customer experience across digital touchpoints for global enterprises. It is estimated that by 2022, 30% of customer experiences will be handled by conversational AI, up from 3% in 2017. A.ware makes it easy to build, train, deploy, and scale conversational AI solutions to drive revenue, reduce costs and increase operational efficiency.
Shridhar Marri, CEO and Co-Founder of Senseforth said, “This strategic investment creates a new growth blueprint for Senseforth.ai. We are thrilled to deliver on our vision 'to make technology humanlike', enabling continuous Human-AI interaction and transforming complex business processes.” He added, “We can now scale talent, accelerate growth, make more investments in R&D, and create incredible value for our clients.”
Announcing the strategic investment, Fractal’s Co-Founder, Group Chief Executive and Vice Chairman, Srikanth Velamakanni said, “Senseforth.ai’s founders Shridhar, Krishna and Ritesh have built a great team and a robust platform that’s deployed at scale with marquee clients like HDFC Bank. Senseforth’s technology is ahead of the competition, especially as evidenced by their performance benchmark on the leaderboard of Stanford Question Answering Dataset (SQuAD) 2.0.” Srikanth added, “We are excited to partner with the Senseforth.ai team to contribute to their next phase of growth.”
“We are inspired by Senseforth.ai’s work with the government of India to remove technology barriers in accessing citizen services for 700 million internet users through conversational AI. We are delighted to partner with Senseforth and expand conversational AI solutions to our clients,” said Pranay Agrawal, Fractal’s Co-founder and Chief Executive Officer.
Krishna Kadiri, Chief AI Officer and Co-Founder of Senseforth said, “Senseforth has a robust R&D and innovation culture and has already made its mark in the global ML benchmarks. This investment will help us enhance our deep learning capabilities and embed advanced cutting-edge research into A.ware.”
Don Vadakan, Chief Sales Officer at Fractal said, “Senseforth’s industry agnostic, multi-experience AI platform will drive next-generation digital solutions. We are excited to deliver powerful use cases across industries for both large and mid-size enterprises with A.ware from Senseforth.”
Ritesh Radhakrishnan, CTO, and Co-Founder of Senseforth said, “At Senseforth.ai, we have built A.ware, one of the most powerful and comprehensive Conversational AI Platforms in the market today. A.ware is already automating billions of conversations for enterprises across the world. This investment will help us further strengthen our technology foundation and scale our platform and products to become the undisputed market leader in the Conversational AI space.”
About Senseforth.ai
Senseforth.ai is a Conversational AI platform that enables automated human-like conversations at scale, between organizations and people. Founded with a vision to “make technology humanlike”, Senseforth.ai helps businesses acquire, engage and assist customers using AI-powered bots. As a preferred partner of choice for enterprises in North America, Europe and APAC, Senseforth.ai has implemented 100+ solutions that handle millions of conversations every month and has been recognized as a ‘Cool Vendor’ in Conversational AI Platforms in 2020 by Gartner, For more information, visit www.senseforth.ai
About Fractal
Fractal is one of the leading providers of AI and analytics globally to the world's most admired Fortune 500® companies. Fractal's mission is to power every human decision in the enterprise by bringing AI, engineering, and design to solve some of the world’s toughest problems.
Fractal's products include Qure.ai, to assist radiologists in making better diagnostic decisions; Crux Intelligence, to assist CEOs, and senior executives make better tactical and strategic decisions; Theremin.ai, to improve investment decisions; Eugenie.ai, to find anomalies in high-velocity data; and Samya.ai to drive next generation enterprise revenue growth management.
Fractal has more than 2,800 employees across 16 global locations, including the United States, UK, Ukraine, India, Singapore and Australia. Fractal has consistently been rated among India's best companies to work for, by The Great Place to Work® Institute; featured as a leader in the Customer Analytics Service Providers Wave™ 2021, Specialized Insights Service Providers Wave™ 2020 & Computer Vision Consultancies Wave™ 2020, by Forrester Research; and recognized as an "Honorable Vendor" in 2021 Magic Quadrant™ for data & analytics by Gartner. For more information visit fractal.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005361/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release
Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release
Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom